Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers

Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis

Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation

CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared with conventional serologic tests alone. AVISE Lupus' enhanced sensitivity and specificity address key diagnostic gaps, supporting an earlier, more definitive Systemic Lupus Erythematosus (SLE) diagnosis, with the potential for earlier intervention, prevention of organ damage and improved long-term outcomes.